Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study.
Hagenaars SC, Dekker LJM, Ravesteijn B, van Vlierberghe RLP, Romijn FPHTM, Verhoeff L, Witkamp AJ, Schenk KE, Keymeulen KBIM, Menke-Pluijmers MBE, Dassen AE, Kortmann BA, de Vries J, Rutgers EJT, van der Burgt YEM, Meershoek-Klein Kranenbarg E, Cobbaert CM, Luider TM, Mesker WE, Tollenaar RAEM. Hagenaars SC, et al. Among authors: meershoek klein kranenbarg e. Int J Mol Sci. 2022 Oct 17;23(20):12399. doi: 10.3390/ijms232012399. Int J Mol Sci. 2022. PMID: 36293255 Free PMC article.
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, Putter H, Duijm-de Carpentier M, Rutgers EJT, Seynaeve C, Bartlett JMS, Vannetzel JM, Rea DW, Hasenburg A, Paridaens R, Markopoulos CJ, Hozumi Y, Portielje JEA, Kroep JR, van de Velde CJH, Liefers GJ. Noordhoek I, et al. J Clin Oncol. 2020 Oct 1;38(28):3273-3281. doi: 10.1200/JCO.19.02427. Epub 2020 Jul 24. J Clin Oncol. 2020. PMID: 32706636
Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer.
Hagenaars SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Pijl H, Putter H, Tollenaar RAEM, Kroep JR, Mesker WE; Dutch Breast Cancer Research Group (BOOG). Hagenaars SC, et al. Int J Cancer. 2021 Sep 1;149(5):1181-1188. doi: 10.1002/ijc.33700. Epub 2021 Jun 5. Int J Cancer. 2021. PMID: 34043821 Free PMC article.
The Impact of Postoperative Complications on Short- and Long-Term Health-Related Quality of Life After Total Mesorectal Excision for Rectal Cancer.
van Kooten RT, Elske van den Akker-Marle M, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Wouters MWJM, Tollenaar RAEM, Peeters KCMJ. van Kooten RT, et al. Among authors: meershoek klein kranenbarg e. Clin Colorectal Cancer. 2022 Dec;21(4):325-338. doi: 10.1016/j.clcc.2022.07.004. Epub 2022 Sep 17. Clin Colorectal Cancer. 2022. PMID: 36210321 Free article.
Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer.
Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, Fruytier SE, Meershoek-Klein Kranenbarg E, Kloet S, van der Burg B, Martens JWM, Sims AH, Turnbull AK, Dixon JM, Verhaegh W, Kroep JR, van de Velde CJH, van de Stolpe A. Inda MA, et al. Mol Cancer Ther. 2020 Feb;19(2):680-689. doi: 10.1158/1535-7163.MCT-19-0318. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727690
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok AE, Liefers GJ, Nortier JWR, Rutgers EJT, van de Velde CJH; IDEAL Study Group. Blok EJ, et al. J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx134. J Natl Cancer Inst. 2018. PMID: 28922787 Clinical Trial.
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL Study Group. Blok EJ, et al. Breast Cancer Res Treat. 2018 Apr;168(2):413-420. doi: 10.1007/s10549-017-4601-1. Epub 2017 Dec 12. Breast Cancer Res Treat. 2018. PMID: 29230665 Free PMC article. Clinical Trial.
62 results